Should You Give Up on Novavax?

2
1
Favorite

Should You Give Up on Novavax?

Motley Fool2023-03-03

During the early days of the pandemic, Novavax (NVAX 9.38%) jumped into the spotlight. That's after its COVID-19 vaccine program won a big investment from the U.S. government. And investors bet on the...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Report

Comment（1）

Hesper7793
·2023-03-04
My Avg too high 😭😭😭
Reply
Like
Report

Most Discussed

7x24

All

Terms and Conditions·Privacy Policy

Company: TTMF Limited. Tech supported by Xiangshang Yixin.

Email：uservice@ttm.financial

{"i18n":{"language":"en_US"},"data":{"share":"https://ttm.financial/m/news/2316096649?lang=en_US&edition=fundamental","thumbnail":"https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F723173%2Fgettyimages-1295986889.jpg&op=resize&w=165&h=104","is_english":true,"pubTime":"2023-03-03 14:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2316096649","market":"us","top_or_hot":-1,"title":"Should You Give Up on Novavax?","media":"Motley Fool","content":"<div>\n<p>During the early days of the pandemic, Novavax (NVAX 9.38%) jumped into the spotlight. That's after its COVID-19 vaccine program won a big investment from the U.S. government. And investors bet on the...</p>\n\n<a href=\"https://www.fool.com/investing/2023/03/03/should-you-give-up-on-novavax/\">Source Link</a>\n\n</div>\n","source":"fool_stock","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Should You Give Up on Novavax?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nShould You Give Up on Novavax?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2023-03-03 14:00 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2023/03/03/should-you-give-up-on-novavax/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>During the early days of the pandemic, Novavax (NVAX 9.38%) jumped into the spotlight. That's after its COVID-19 vaccine program won a big investment from the U.S. government. And investors bet on the...</p>\n\n<a href=\"https://www.fool.com/investing/2023/03/03/should-you-give-up-on-novavax/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4585","symbol_name":"ETF&股票定投概念","start_time":0,"source_url":"https://www.fool.com/investing/2023/03/03/should-you-give-up-on-novavax/","article_id":"2316096649","we_media_id":null,"thumbnails":["https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F723173%2Fgettyimages-1295986889.jpg&op=resize&w=165&h=104"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2316096649","pubTimestamp":1677823200,"columns":[],"sourceInfo":{"source_id":"fool_stock","name":"Motley Fool"},"weMediaInfo":null,"summary":"After a spectacular 2020 performance, Novavax's shares have plummeted.","collect":0,"end_time":0,"defaultTopTitle":"fool.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4585":"ETF&股票定投概念","BK4139":"生物科技","BK4588":"碎股","BK4568":"美国抗疫概念","NVAX":"诺瓦瓦克斯医药"},"translate_title":"你应该放弃诺瓦瓦克斯吗？","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NVAX":1},"content_text":"During the early days of the pandemic, Novavax (NVAX 9.38%) jumped into the spotlight. That's after its COVID-19 vaccine program won a big investment from the U.S. government. And investors bet on the company's ability to bring its vaccine candidate to market. As a result, the shares skyrocketed, gaining more than 2,700% in a year.But Novavax went on to disappoint investors. It won regulatory authorization a year after rivals, so it missed out on the initial big wave of demand and sales. Since then, the company hasn't been able to carve out much market share, and the stock has plummeted. In the fourth-quarter earnings report, the situation shifted from bad to worse. Novavax said various uncertainties exist, and they could lead to the company shutting its doors. Is it time to give up on this embattled stock? Let's take a closer look.Lower-than-expected salesFirst, some background on what's happened so far. Novavax's revenue climbed last year for one simple reason. Last year represented its first full year of sales for the coronavirus vaccine, Novavax's only commercialized product. Total revenue rose 73% to $1.9 billion. The problem is revenue was lower than the $4 billion to $5 billion the company predicted earlier in the year.Most people who wanted a primary series already got it, resulting in a decline in demand and less need for Novavax's product. Today, Novavax's vaccine may be used as a booster. But here, too, Novavax won regulatory nods after rivals Pfizer and Moderna. At the same time, Novavax's expenses have climbed due to the costs of commercializing the vaccine.In recent times, headwinds have multiplied. The company's partner in Japan, Takeda, said the country cancelled further purchases of Novavax's vaccine. The initial agreement covered 150 million doses. The cancellation means more than 141 million doses won't be bought by Japan.Novavax also is facing a dispute with Gavi, the Vaccine Alliance. The company ended its purchase agreement with Gavi, saying the organization failed to order the agreed upon number of vaccine doses last year. But Gavi says Novavax wouldn't be able to fulfill its manufacturing promises.Finally, the U.S. government has said its funding agreement with Novavax wouldn't continue beyond the end of this year. And that means Novavax could miss out on more than $400 million. The company is discussing potential solutions with the government. But the situation remains a risk.Whether the company survivesWhat happens with U.S. funding and the Gavi dispute could help determine whether the company survives. Novavax's financial future also will depend on its ability to provide a vaccine updated with the latest strains for the fall vaccination season. Novavax's vaccine manufacturing process takes more time than that of Pfizer and Moderna. That could set Novavax behind -- something that would be disastrous for sales.Right now, Novavax's forecasts suggest it has enough cash to continue operations through the coming year. But the risks mentioned above could change that.\"Given these uncertainties, substantial doubt exists regarding our ability to continue,\" the company said in its earnings report.What does this mean for investors?In the past, I've talked about Novavax's chances to excel in the long-term coronavirus vaccine market. The company is studying a promising combined flu/coronavirus candidate in phase 2 trials. But to reach success with that potential product, Novavax must have the financial strength to survive. Today, the company itself has pointed to doubts -- and that's not good news for investors.So, should you give up on Novavax? It depends on your tolerance for risk and whether you already own the shares. If you're a shareholder, you might consider holding instead of selling at a loss. Novavax stock has dropped about 97% since its peak in 2021.Now, the biotech is making big efforts to cut costs and turn today's difficult situation around. It might be successful. And any good news could significantly lift the stock.But if you don't own Novavax already, my best advice is to wait and watch the company's progress this year. Getting in on this story today is way too risky.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[{"id":9940621042,"gmtCreate":1677886900787,"gmtModify":1677886906558,"author":{"id":"4113632054268172","authorId":"4113632054268172","name":"Hesper7793","avatar":"https://community-static.tradeup.com/news/0e89f6f9c49b322652f17e906e75447f","vip":1,"hat":"https://static.tigerbbs.com/f84d87792f02cf78e80ee34979fd31e5","crmLevel":4,"crmLevelSwitch":1,"idStr":"4113632054268172","authorIdStr":"4113632054268172"},"htmlText":"My Avg too high 😭😭😭","listText":"My Avg too high 😭😭😭","text":"My Avg too high 😭😭😭","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9940621042","repostId":2316096649,"repostType":2,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"}],"hasMoreComments":true,"newsSizeData":{"likeSize":2,"commentSize":1,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false}}